Latest Insider Transactions at Centessa Pharmaceuticals PLC (CNTA)
This section provides a real-time view of insider transactions for Centessa Pharmaceuticals PLC (CNTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Centessa Pharmaceuticals plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Centessa Pharmaceuticals plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2022
|
Antoine Yver EVP & Chairman of Development |
SELL
Open market or private sale
|
Direct |
20,222
-2.43%
|
$101,110
$5.42 P/Share
|
|
Mar 21
2022
|
Francesco De Rubertis Director |
BUY
Other acquisition or disposition
|
Indirect |
1,839,265
+13.81%
|
-
|
|
Mar 21
2022
|
Marella Thorell Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
52,101
+49.52%
|
-
|
|
Mar 21
2022
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,839,265
+13.81%
|
-
|
|
Feb 02
2022
|
Saurabh Saha Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+15.15%
|
$45,000
$9.74 P/Share
|
|
Jan 28
2022
|
David J Grainger Chief Innovation Officer |
BUY
Open market or private purchase
|
Indirect |
27,500
+50.0%
|
$247,500
$9.05 P/Share
|
|
Dec 02
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
34,326
+0.84%
|
$411,912
$12.82 P/Share
|
|
Dec 02
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,326
+0.84%
|
$411,912
$12.82 P/Share
|
|
Dec 01
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
60,304
+1.49%
|
$723,648
$12.62 P/Share
|
|
Dec 01
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,304
+1.49%
|
$723,648
$12.62 P/Share
|
|
Nov 30
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
36,847
+0.93%
|
$405,317
$11.62 P/Share
|
|
Nov 30
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
36,847
+0.93%
|
$405,317
$11.62 P/Share
|
|
Nov 29
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
56,706
+1.43%
|
$623,766
$11.7 P/Share
|
|
Nov 29
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
56,706
+1.43%
|
$623,766
$11.7 P/Share
|
|
Nov 26
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
11,817
+0.31%
|
$129,987
$11.34 P/Share
|
|
Nov 26
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,817
+0.31%
|
$129,987
$11.34 P/Share
|
|
Nov 18
2021
|
Aaron Kantoff Director |
BUY
Open market or private purchase
|
Direct |
10,000
+14.29%
|
$110,000
$11.98 P/Share
|
|
Nov 16
2021
|
Tia L Bush Chief Technology & Quality Ofc |
BUY
Open market or private purchase
|
Indirect |
5,000
+26.65%
|
$60,000
$12.33 P/Share
|
|
Nov 16
2021
|
Saurabh Saha Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
23,000
+50.0%
|
$276,000
$12.28 P/Share
|
|
Jun 02
2021
|
Gregory M Weinhoff Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$200,000
$20.0 P/Share
|
|
Jun 02
2021
|
Marella Thorell Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$20,000
$20.0 P/Share
|
|
Jun 02
2021
|
Arjun Goyal Director |
BUY
Open market or private purchase
|
Indirect |
750,000
+16.02%
|
$15,000,000
$20.0 P/Share
|
|
Jun 02
2021
|
Arjun Goyal Director |
BUY
Conversion of derivative security
|
Indirect |
3,181,818
+50.0%
|
-
|
|
Jun 02
2021
|
Iqbal J Hussain General Counsel |
BUY
Open market or private purchase
|
Indirect |
5,500
+50.0%
|
$110,000
$20.0 P/Share
|
|
Jun 02
2021
|
Iqbal J Hussain General Counsel |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$60,000
$20.0 P/Share
|
|
Jun 02
2021
|
Thomas Templeman Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
250
+50.0%
|
$5,000
$20.0 P/Share
|
|
Jun 02
2021
|
Tia L Bush Chief Technology & Quality Ofc |
BUY
Open market or private purchase
|
Indirect |
3,000
+50.0%
|
$60,000
$20.0 P/Share
|
|
Jun 02
2021
|
David M Chao Chief Administrative Officer |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$10,000
$20.0 P/Share
|
|
Jun 02
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+13.54%
|
$12,000,000
$20.0 P/Share
|
|
Jun 02
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,931,818
+37.42%
|
-
|
|
Jun 02
2021
|
Francesco De Rubertis Director |
BUY
Open market or private purchase
|
Indirect |
600,000
+13.54%
|
$12,000,000
$20.0 P/Share
|
|
Jun 02
2021
|
Francesco De Rubertis Director |
BUY
Conversion of derivative security
|
Indirect |
1,931,818
+37.42%
|
-
|
|
Jun 02
2021
|
Gap (Bermuda) L.P. Director |
BUY
Open market or private purchase
|
Direct |
1,500,000
+13.41%
|
$30,000,000
$20.0 P/Share
|
|
May 27
2021
|
Antoine Yver EVP & Chairman of Development |
BUY
Grant, award, or other acquisition
|
Direct |
833,897
+50.0%
|
-
|